Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin alfa in STEMI
NCT01043991Phase 3Completed
- Sponsor
- CHU Montpellier
- Start
- Dec 2008
- Primary completion
- Jul 2010
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of darbepoetin alfa in ST-segment elevation myocardial infarction (STEMI), sponsored by CHU Montpellier. Primary endpoint: Magnetic resonance imaging determination of infarct size at 12 weeks. Started Dec 2008; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT01043991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01043991.